View Drug Tariff Part IX
Detailed information on Part IX of the Drug Tariff
Part IX Advanced Services
Declaration for Advanced Services
In line with the current arrangements for reimbursement of products in Part IX and remuneration, dispensing appliance contractors (DACs) and pharmacy contractors may choose to provide either one or both of the following advanced services:
- stoma appliance customisation
- appliance use reviews
DACs and pharmacy contractors wishing to provide either one or both Advanced Services must make an initial, one-off declaration to NHS Prescription Services stating their intentions.
To declare your intentions, please submit the Advanced Services declaration form to NHS Prescription Services.
Completed applications must be with NHS Prescription Services no later than the last day of the month prior to the month in which the services are intended to be provided.
A DAC or pharmacy contractor who wishes to offer the Advanced Services of stoma customisation and/or AURs will also need to notify the relevant Area Team of their intention to provide advanced services.
If a DAC or pharmacy contractor wishes to withdraw stoma customisation, 3 months' notice must be given to both NHS Prescription Services and the relevant Area Team of their intention to do so.
Advanced Services requirements are set out in The Pharmaceutical Services (Advanced Services) (Appliances) (England) Directions 2009 in Part VIE of the Drug Tariff.
Part IX price increase mechanism
Following the suspension of the price increase mechanism for products in Part IX of the Drug Tariff, the price increase mechanism was re-instated in April 2007 for products in Part IXA (excluding catheters) and Part IXR.
On 1 October 2010 the reimbursement price increase mechanism was re-introduced for Part IXA catheters, Part IXB and Part IXC.
Applications for price increases should be sent by companies so as to be received by NHS Prescription Services two months before the price rise is intended to take effect; for example price rises requested between 1 October and 31 October will be effective for the January Drug Tariff.
Companies can not request a price increase earlier than two months before it takes effect. The maximum price rise will be calculated as being the forecast of the gross domestic product (GDP) deflator minus 0.75. The GDP deflator currently being used to calculate the annual price increase is 1.48%.
All generic products will continue to receive their price increase in June each year.
Part IX applications
(Last updated 19 January 2018)
At the moment we are reviewing applications for listing in Part IX of the Drug Tariff acknowledged on 14 December 2017. There are currently 20 applications awaiting assessment.
87 applications require further information from the manufacturer.
Please be aware that the NHSBSA is dealing with a large number of applications at the moment. To minimise delay, please ensure that applications are complete and samples are provided as requested.
The timeline published in the document ‘An Introduction to Part IX of the Drug Tariff’ is for guidance only. Please use the tracker above in combination with the timeline to gauge progress of applications.
Part IXR chemical reagents declaration form
Following the results of the Department of Health consultation “Arrangements for the Provision of Dressings & Chemical Reagents to Primary Care”, manufacturers of certain chemical reagents are required to provide notification in writing of their continued commitment to maintain free services to support the use of their reagent products.
The Department of Health stated that Ministers had taken the decision to implement a staged reduction of up to 15% to the April 2006 Drug Tariff reimbursement prices for some blood glucose detection strips. A reduction of 12% was applied to the reimbursement prices for some chemical reagents on 1 October 2006.
The staged approach was recognition on the Department’s behalf of observations about the desirability of maintaining the number of free services offered by manufacturers in support of patient use of products. These free services include the supply of educational material, meters and the provision of helplines and should continue to be provided in the same quantities and the same quality as they were provided prior to the consultation.
The additional 3% will not be applied to the products of a manufacturer as long as that manufacturer is in a position to maintain the services it currently offers in support of the patient use of its products. However, the Department has indicated that it is open to representations about the withdrawal of particular services.
Representation regarding the withdrawal of services must be made to the Pharmaceutical Services Manager at NHS Prescription Services at least six weeks before the self-declaration date.
The self-declaration form is intended to be the most practical approach administratively and the fairest in terms of our openness to listen to future representations.
Failure to provide the self-declaration form or a change to the level of service provided without prior agreement by the Department of Health will result in a further price reduction being applied from the first of the month in which the services were to have been provided.
Following feedback from suppliers this has now changed from a quarterly to an annual requirement. The CRSDF01 form allows manufacturers to confirm service provision until 31 March 2018 and should be received by the NHS Business Services Authority by 28 February 2017.
The next form covering 1 April 2018 to 31 March 2019 will be due by 28 February 2018. This will be available on this website from early 2018.
Part IXA: appliances not available at the Drug Tariff listed price
NHS Prescription services would be interested to know from any pharmacy or dispensing appliance contractors who are unable to obtain Part IXA appliances at the Drug Tariff listed price.
If you are a contractor and unable to obtain an item listed in Part IXA at the price listed from your normal wholesaler, or directly from the manufacturer/supplier, please email the NHSBSA at email@example.com.
Part IX Annual review 2016-17
Part IX Guidance to manufacturers and suppliers of medical devices